Beylergil, V., Collins, L., Schwartz, L. H., Eche, T., Zhao, B., Champiat, S., Carvajal, R., Abedin, S. E., & Dercle, L. (2025). Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp. European Journal of Cancer, 220, 115386. https://doi.org/10.1016/j.ejca.2025.115386

Fahmy, L. M., Schreidah, C. M., McDonnell, D. E., Carvajal, R. D., Magro, C. M., & Geskin, L. J. (2024). Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal, 29(6). https://doi.org/10.5070/d329662993

Servais, L., Day, J. W., De Vivo, D. C., Kirschner, J., Mercuri, E., Muntoni, F., Proud, C. M., Shieh, P. B., Tizzano, E. F., Quijano-Roy, S., Desguerre, I., Saito, K., Faulkner, E., Benguerba, K. M., Raju, D., LaMarca, N., Sun, R., Anderson, F. A., & Finkel, R. S. (2024). Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. Journal of Neuromuscular Diseases, 11(2), 425–442. https://doi.org/10.3233/jnd-230122

Thomsen, G., Burghes, A. H. M., Hsieh, C., Do, J., Chu, B. T. T., Perry, S., Barkho, B., Kaufmann, P., Sproule, D. M., Feltner, D. E., Chung, W. K., McGovern, V. L., Hevner, R. F., Conces, M., Pierson, C. R., Scoto, M., Muntoni, F., Mendell, J. R., & Foust, K. D. (2021). Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nature Medicine, 27(10), 1701–1711. https://doi.org/10.1038/s41591-021-01483-7

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., … Piperno-Neumann, S. (2021). Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 385(13), 1196–1206. https://doi.org/10.1056/nejmoa2103485